Anti-NMDAR encephalitis in Crohn’s disease undergoing long-term infliximab treatment: A case report
Frontiers in Immunology, 2022 Infliximab, a chimeric monoclonal antibody against anti-tumor necrosis factor-α (TNF-α), has revolutionized the management of inflammatory bowel disease. However, a recent nested case-control study showed that anti-TNF-α therapy exposure in patients with
Shin Ju Oh +3 more
doaj +1 more source
CD3+CD4+LAP+Foxp3-regulatory cells of the colonic lamina propria limit disease extension in ulcerative colitis [PDF]
, 2018 Background and Aims: In ulcerative colitis (UC), inflammation begins in the rectum and can extend proximally throughout the entire colon. The extension of inflammation is an important determinant of disease course, and may be limited by the action of ...
Amendola, Antonello +10 more
core +3 more sources
Smoking in inflammatory bowel diseases: Good, bad or ugly? [PDF]
, 2007 Smoking is an important environmental factor in inflammatory bowel disease (IBD), having different effects in ulcerative colitis (UC) and Crohn’s disease (CD).
Lakatos, László +2 more
core +1 more source
The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe
BMC Gastroenterology, 2021 Background Ulcerative colitis (UC) is an inflammatory bowel disease with increasing prevalence worldwide. Current treatment strategies place considerable economic and humanistic burdens on patients.
Leonardo Ruiz-Casas +14 more
doaj +1 more source
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
New England Journal of Medicine, 2019 BACKGROUND The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown.
B. Sands +15 more
semanticscholar +1 more source
Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models [PDF]
Intestinal Research, 2020 The specific pathogenesis underlining inflammatory bowel disease (IBD) is very complicated, and it is further more difficult to clearly explain the pathophysiology of 2 major forms of IBD, Crohn’s disease (CD) and ulcerative colitis (UC), and both ...
Emiko Mizoguchi +3 more
doaj +1 more source
Influence of Crohn’s disease related polymorphisms in innate immune function on ileal microbiome [PDF]
, 2019 We have previously identified NOD2 genotype and inflammatory bowel diseases (IBD) phenotype, as associated with shifts in the ileal microbiome (“dysbiosis”) in a patient cohort.
Ciorba, Matthew A +13 more
core +3 more sources
Protective and Aggravating Effects of Nlrp3 Inflammasome Activation in IBD Models: Influence of Genetic and Environmental Factors [PDF]
, 2012 Background: Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation due to dysregulation of the mucosal immune system.
Bauer, Christian +4 more
core +1 more source
Comparative study of under-expressed prognostic biomarkers and pivotal signaling pathways in colon cancer and ulcerative colitis using integrated bioinformatics approach [PDF]
arXiv, 2023 Colon cancer is a prevalent gastrointestinal malignancy arising in the colon. Ulcerative colitis(UC) is one of the risk factors of colorectal cancer. The detection of under-expressed biomarkers and molecular mechanisms in UC and colon cancer can lead to effective management of colitis-associated cancer. A total of two mRNA expression datasets (GSE87473
arxiv
Annals of Oncology, 2017 Background Ipilimumab, an immune checkpoint inhibitor targeting CTLA-4, prolongs survival in a subset of patients with metastatic melanoma (MM) but can induce immune-related adverse events, including enterocolitis.
N. Chaput +17 more
semanticscholar +1 more source